MGNX
MacroGenics, Inc.
stockNASDAQ
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. the combination of macrogenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.60 | 2026-10-01 | -1.25% | 3.829 |
| 1M | 4.32 | 2026-09-08 | -17.71% | 0.691 |
| 3M | 4.66 | 2026-07-08 | -23.71% | 1.073 |
| 6M | 3.45 | 2026-04-08 | +3.04% | 0.734 |
| 1Y | 1.78 | 2025-10-08 | +99.72% | 0.925 |
| 2Y | 3.62 | 2024-10-08 | -1.80% | — |
| 5Y | 20.63 | 2021-10-08 | -82.77% | 1.461 |
MacroGenics, Inc. (NASDAQ:MGNX) stock price today is $3.56, and today's volume is 488,738. MGNX is up 0.141% today. The 30 day average volume is 558,942. MGNX market cap is $226.45M with 63.70M shares outstanding.